Search

Incyte Corp

Închisă

SectorSănătate

119.5 1.28

Rezumat

Modificarea prețului

24h

Curent

Minim

114.9

Maxim

119.77

Indicatori cheie

By Trading Economics

Venit

-1.4B

-785M

Vânzări

-117M

1.6B

P/E

Medie Sector

61.245

51.78

EPS

-3.79

Marjă de profit

-50.398

Angajați

2,844

EBITDA

-1.5B

-688M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.86% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.5B

24B

Deschiderea anterioară

118.22

Închiderea anterioară

119.5

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 nov. 2026, 21:07 UTC

Incyte Corp's shares are advancing, supported by a broader market increase since Thursday, recovering from an early dip and positioning above its 20-day moving average.

5 nov. 2026, 21:04 UTC

Incyte Corp shares are declining amid a broader market downturn, influenced by economic data showing falling jobless claims and rising productivity.

4 nov. 2026, 21:02 UTC

News

Incyte Corp will present over 30 abstracts at the ASH Annual Meeting, including Phase 1 data for INCA033989 and updates on myelofibrosis treatments.

3 nov. 2026, 21:41 UTC

Incyte Corp shares are declining in after-market trading, marking the fourth consecutive session of lower closes and reaching a low below Tuesday's close.

2 nov. 2026, 20:26 UTC

News

Bernstein SocGen's Jeffrey Walch raises Incyte Corp's price target to $108.00 from $104.00 while maintaining a Market Perform rating.

30 oct. 2026, 23:16 UTC

Incyte Corp shares are modestly higher in after-market hours, remaining 5.89% above their 20-day moving average and near the upper end of their one-month range.

29 oct. 2026, 23:01 UTC

Incyte Corp is trading higher in after-market hours, reaching a high point and well above its 20-day moving average since Thursday's close.

28 oct. 2026, 20:07 UTC

Macro Event

Incyte Corp shares are advancing as investors monitor the Federal Reserve's decision to maintain interest rates amid rising inflation, despite an earlier pullback.

27 oct. 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading after initially rising, reflecting significant volatility within the broader context of its one-month trading range.

26 oct. 2026, 21:01 UTC

Incyte Corp shares advanced modestly in after-market trading, maintaining a cumulative return of 0.83% since Monday's close.

23 oct. 2026, 20:07 UTC

Incyte Corp shares are declining amid a broader market downturn influenced by rising oil prices, inflation concerns, and geopolitical tensions.

22 oct. 2026, 20:07 UTC

Incyte Corp shares are advancing, continuing a notable upward trajectory since Wednesday's close, reaching their peak just before the close on Thursday.

21 oct. 2026, 20:07 UTC

Incyte Corp shares are declining, reflecting broader market weakness, and are approaching the low end of their one-month range amid a significant drop since Tuesday's close.

20 oct. 2026, 20:08 UTC

News

Morgan Stanley initiates coverage on Incyte Corp with an Equalweight rating and a price target of $119.00, following the stock's prior close of $113.25.

19 oct. 2026, 19:36 UTC

News

Incyte Corp will present new data on investigational therapies INCB161734 and INCA33890 at the ESMO Congress 2026, scheduled for October 23 to 27 in Madrid.

17 oct. 2026, 00:01 UTC

Incyte Corp shares are trading lower in after-market hours, reversing an initial gain and reaching their lowest point of the day.

16 oct. 2026, 20:13 UTC

Incyte Corp shares are modestly higher in after-market trading, maintaining a slight gain.

15 oct. 2026, 21:03 UTC

Incyte Corp shares are advancing in after-market trading, continuing a strong performance after three consecutive sessions of gains, though still below the 20-day moving average.

14 oct. 2026, 20:07 UTC

News

Truist Securities maintains Hold rating on Incyte Corp and raises price target to $115 in a report published today.

13 oct. 2026, 20:02 UTC

Social Media

Incyte Corp shares fell sharply, reaching a low point shortly after the market opened and remaining below its 20-day moving average.

12 oct. 2026, 21:01 UTC

Incyte Corp shares declined in after-market trading, continuing a downward trend and remaining notably below its 20-day moving average.

9 oct. 2026, 20:07 UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

8 oct. 2026, 20:07 UTC

News

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

7 oct. 2026, 21:31 UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

6 oct. 2026, 19:50 UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

5 oct. 2026, 21:01 UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2 oct. 2026, 23:05 UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

1 oct. 2026, 23:15 UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

30 sept. 2026, 20:01 UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

29 sept. 2026, 20:07 UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

13.86% sus

Prognoză pe 12 luni

Medie 134.368 USD  13.86%

Maxim 157 USD

Minim 108 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

21 ratings

10

Cumpărare

11

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat